• share
• favorite_border

A new study from the Uniformed Services University (USU), "Rethinking Shadowing for Aspiring Physicians", published in the New England Journal of Medicine, challenges the traditional emphasis on physician shadowing as a key criterion for medical school admission, highlighting its financial and accessibility barriers for many aspiring doctors.

• share
• favorite_border

The FDA approval was based on results from the CABINET study, a phase 3 pivotal trial evaluating cabozantinib compared with placebo in two groups of patients with previously treated NETs: advanced pancreatic NETs and advanced extra-pancreatic NETs. The study was led by Jennifer Chan, MD, MPH, clinical director of the gastrointestinal cancer center and director of the program in carcinoid and neuroendocrine tumors at Dana-Farber Cancer Institute.

• share
• favorite_border

Two new drugs offer chance for patients who don鈥檛 respond to existing treatments to break through the 鈥渢herapeutic ceiling鈥� for ulcerative colitis.

• share
• favorite_border

A modified bone marrow transplant procedure for sickle cell disease (SCD) co-developed at Vanderbilt University Medical Center, Johns Hopkins University School of Medicine, and the University of California, San Francisco, can cure the disease, a new study has found.

• share
• favorite_border

An artificial intelligence (AI) program can identify chronic liver disease from videos taken during a common heart test known as an echocardiogram, Cedars-Sinai investigators report.

• share
• favorite_border

A Penn Medicine pilot study shows it鈥檚 possible to use digital technology to safely reduce the amount of time some patients with cancer spend receiving care.

• share
• favorite_border

Combining bupropion medication and a behavioral counseling program dramatically increased quit rates among people living with HIV who smoked.

• share
• favorite_border

People living with tricuspid valve disease are gaining more treatment options, driven by research from Cedars-Sinai investigators and collaborators at other leading medical institutions.

• share
• favorite_border

Set to enter hospice care, a patient with idiopathic multicentric Castleman鈥檚 disease is now in remission after treatment with a medication identified by an AI-guided analysis

• share
• favorite_border

Shoulder symptoms led to an average of 9.6 million physician visits in 2015 and 2016 in the United States.The most common cause of those shoulder symptoms?Rotator-cuff disorders.Tears of the rotator cuff can result from a substantial traumatic injury or can occur slowly over time.

• share
• favorite_border

鈥� Study finds three new safe and effective drug regimens to fight multidrug-resistant TB 鈥� The treatments, which include recently discovered TB drugs, give new options for shorter, personalized treatment and are cleared for use for more people than ever

• share
• favorite_border

The University of Chicago Medicine has launched a Phase 2 clinical trial to study how CAR T-cell therapy could be used to treat three autoimmune diseases.

• share
• favorite_border

A study led by Rutgers professor finds more liberal blood transfusions have more favorable results

• share
• favorite_border

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk SMM carries a higher likelihood of progression.

• share
• favorite_border

Researchers at Children鈥檚 Hospital of Philadelphia (CHOP) and the Children鈥檚 Oncology Group (COG) announced the results of a Phase 3 study that demonstrated adding the bi-specific T-cell engager, blinatumomab, to chemotherapy for newly diagnosed National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) pediatric patients significantly improves survival outcomes. The results were published today in the New England Journal of Medicine and will be presented during the plenary session at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego on December 8.

• share
• favorite_border

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene autoleucel (obe-cel), experienced high response rates and most did not need a subsequent stem cell transplant (SCT), according to results from the Phase Ib/II FELIX trial co-led by researchers at The University of Texas MD Anderson Cancer Center.

• share
• favorite_border